Skip Navigation

Asthma (uncontrolled) - omalizumab

Omalizumab for severe persistent allergic asthma

Guidance type:  Technology appraisal
Date issued:  November 2007

We will consult on our review plans for this guidance in August 2010.

Reference:  TA133

Summary

Omalizumab is recommended as a possible treatment for adults and young people over 12 years with severe persistent allergic asthma when all of the following circumstances apply.

  • When the person's asthma is still severe and unstable despite best efforts to control it with other asthma medicines taken as directed by their doctor.
  • When the person has stopped smoking, if their doctor feels it is appropriate.
  • When the person has allergic asthma. This should be confirmed by checking past symptoms and skin testing for allergies.
  • When the person has had at least two asthma attacks within the past year that have needed admission to hospital, or when the person has had three or more severe asthma attacks within the past year, one of which has needed admission to hospital and the other two have needed additional treatment in an accident and emergency department.

Omalizumab treatment should be given along with the person's current asthma medicines. It should be prescribed by a doctor who is experienced in asthma and allergy medicine at a specialist centre.

If omalizumab does not control the asthma after 16 weeks, treatment should be stopped.

Top

Documents

For healthcare professionals

For patients, carers and the public

Background information

Implementing this guidance

Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:

Top

Search NICE guidance


Advanced guidance search

Related guidance

Click the links below to see guidance on similar topics